Antibody Therapeutics(IF=4.5, Oxford University Press) 🎇📷 Novel Modality | Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design academic.oup.com/abt/article/... #SingleDomainAntibody #LightChainOnly #BispecificAntibody

#CellBio2025 in Philadelphia has come to a close!
Thanks to everyone who stopped by the #NanoTag booth 🦙 – great conversations and insights all around.
We were excited to hear how our sdAb tools are driving your new discoveries 📄👏

#SingleDomainAntibody
#ALFAsystem
#SmartSecondaries

Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design AbstractBackground. As one of the most promising classes of next-generation antibody therapeutics, bispecific antibodies (bsAbs) have gained increasing att

A new paper just reached "corrected proof" stage on our journal @antibodytx.bsky.social titled "Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design".

doi.org/10.1093/abt/...

#Antibody #SingleDomainAntibody #Bispecific #OpenAccess